Tarsus Pharmaceuticals Inc. (TARS) Fundamentals

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.
SHARE INFORMATION
Market Cap$ 360,684,640
Shares Outstanding26,327,346
Float19,417,077
Percent Float73.75%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 57,027,000
Latest Fiscal EPS$ -0.72
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions126
Institutional Holdings Date2022-04-30
Institutional Bought Previous 3 Months513,360
Institutional Holdings Percent89.1%
Institutional Sold Previous 3 Months98,990
Insider Holdings Date2022-03-31
Insider Bought Previous 3 Months897,234
Insider Holdings Percent7.3
Insider Sold Previous 3 Months-
Insider Shares Owned1,518,614
TRADING INFO
52 Week High$ 39.08
52 Week Low$ 10.80
52 Week High Change$ -56.49
21 Day Moving Average$ 14.4052
21 Day Extended Moving Average$ 14.1871
50 Day Moving Average$ 16.3484
50 Day Extended Moving Average$ 15.8641
200 Day Moving Average$ 21.5245
200 Day Extended Moving Average$ 21.4777
10 Day Average Volume293,582
20 Day Average Volume377,147
30 Day Average Volume265,352
50 Day Average Volume179,067
Alpha-0.007477
Beta1.4485
Standard Deviation0.222447
R20.095666
7 Day Price Change$ 0.57
7 Day Percent Change4.34%
21 Day Price Change$ -4.61
21 Day Percent Change-25.18%
30 Day Price Change$ -4.85
30 Day Percent Change-26.15%
Month to Date Price Change$ -4.61
Month to Date Percent Change-25.18%
Quarter to Date Price Change$ -3.12
Quarter to Date Percent Change-18.55%
180 Day Price Change$ -11.37
180 Day Percent Change-45.35%
200 Day Price Change$ -14.55
200 Day Percent Change-51.5%
Year to Date Price Change$ -8.80
Year to Date Percent Change-39.11%

Tarsus Pharmaceuticals Inc. (TARS) Key Ratios

PROFITABILITY
EBIT Margin-175.7%
EBITDA Margin-174.5%
Pre-Tax Profit Margin0.0%
Profit Margin Count-24.25%
Gross Margin96.6%
Profit Margin TOT-24.25%
INCOME STATEMENTS
Revenue$ 24,134,000
Revenue Per Share$ 0.9167
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book2.40
Total Debt To Equity0.10
Int Coverage0.00
Current Ratio14.20
Leverage Ratio1.10
Quick Ratio13.90
Long Term Debt To Capital0.12
VALUATION MEASURES
PE Ratio-6.30
Enterprise Value$ 205,797,640
Price to Sales14.9451
Price to Free Cash-1,141.40
PE High Last 5 Years0.00
Price To Book2.40
Price To Cash Flow1,105.00
PE Low Last 5 Years0.00
Price to Tangible Book2.40
MANAGEMENT EFFECTIVENESS
Receivables Turnover1.50
Invoice Turnover0.00
Assets Turnover0.10
Return Assets-23.63
Return on Equity-26.68
Return on Capital-25.09

Tarsus Pharmaceuticals Inc. (TARS) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorErnst & Young LLP
CEOBobak Azamian
Emplyoees46
Last AuditUQ
CIK0001819790
IndustryBiotechnology
SectorHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)(541714)
CONTACT INFO
Address15440 Laguna Canyon Road
Suite 160
Irvine, CA 92618
Websitehttps://www.tarsusrx.com
Facsimile-
Telephone+1 949 409-9820
Emailinfo@tarsusrx.com
Your Recent History
NASDAQ
TARS
Tarsus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20220523 21:55:57